Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MIF | P14174 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14355196 | 0.84 | NOS2 (0.96) | NOS2LMNAMIFADRA2AADRA2C | |
| SCHEMBL8082501 | 0.80 | NOS2 (0.47) | NOS2LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL6682638 | 0.78 | NOS2 (0.46) | NOS2LMNACYP2C19ADRA2AADRA2C | |
| Hydrochloric Acid SCHEMBL8079624 | 0.78 | NOS2 (0.46) | NOS2LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL6682071 | 0.78 | NOS2 (0.46) | NOS2LMNACYP2C19ALDH1A1 | |
| SCHEMBL22180009 | 0.78 | NOS2 (0.46) | NOS2NOS3 | |
| SCHEMBL20487491 | 0.78 | CA12 (0.48) | NOS2ALDH1A1 | |
| SCHEMBL20486524 | 0.77 | ANPEP (0.51) | NOS2LMNACYP2C19HIF1AKDM4E | |
| Acetic Acid SCHEMBL11168239 | 0.77 | NOS2 (0.62) | NOS2LMNACYP2C19MIFNOS3 | |
| Hydrochloric Acid SCHEMBL7327781 | 0.77 | CA12 (0.47) | NOS2CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656953-B2 | Inhibition of cell proliferation | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-05-23 | — | — | US | disclosed |
| US-20140221658-A1 | INHIBITION OF CELL PROLIFERATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-08-07 | — | — | US | disclosed |
| US-8642278-B2 | Inhibition of cell proliferation | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-02-04 | — | — | US | disclosed |
| US-20070254318-A1 | INHIBITION OF CELL PROLIFERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-01 | — | — | US | disclosed |
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254318-A1 | INHIBITION OF CELL PROLIFERATION | RB1, RAF1, NRAS | NOS2 3935/4885LMNA 4361/4885CYP2C19 4650/4885 |
| US-20140221658-A1 | INHIBITION OF CELL PROLIFERATION | RB1, RAF1, NRAS | NOS2 3935/4885LMNA 4361/4885CYP2C19 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.